Related Experiment Video
Updated: Apr 14, 2026

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
Published on: January 7, 2019
Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Infective Endocarditis Outcomes in Japan: A Nationwide
Takahiro Kuno1, Yoshiaki Ohyama1,2, Yoko Sumita3
1Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine Gunma Japan.
Insights
The COVID-19 pandemic did not significantly alter in-hospital mortality for infective endocarditis (IE) patients in Japan after risk adjustment. While unadjusted mortality was higher post-pandemic, valve surgery rates remained stable, though stroke incidence increased.
Area of Science:
- Cardiology
- Infectious Diseases
- Public Health
Background:
- Infective endocarditis (IE) poses a significant mortality risk.
- The COVID-19 pandemic has impacted healthcare systems globally.
- The effect of the pandemic on IE outcomes in Japan is not well understood.
Purpose of the Study:
- To assess the impact of the COVID-19 pandemic on in-hospital mortality for IE patients in Japan.
- To evaluate changes in valve surgery rates among IE patients during the pandemic.
- To analyze the association between the pandemic and IE patient outcomes in Japan.
Main Methods:
- Retrospective analysis of the Japanese registry of all Cardiac and Vascular Diseases Diagnostic Procedure Combination (JROAD-DPC) database.
- Inclusion of 19,077 adult patients hospitalized with IE from April 2016 to March 2022.
- 1:1 propensity score matching to compare pre-COVID-19 and post-COVID-19 periods (6,652 pairs).
Main Results:
- Unadjusted in-hospital mortality was higher in the post-COVID-19 period (15.7% vs. 13.9%, P<0.001).
- Risk-adjusted in-hospital mortality showed no significant difference between periods (15.7% vs. 15.3%, P=0.60).
- Valve surgery rates (26.4% vs. 25.5%, P=0.22) and stroke incidence (8.3% vs. 7.3%, P=0.049) were analyzed.
Conclusions:
- Risk-adjusted in-hospital mortality for infective endocarditis was not significantly different during the COVID-19 pandemic in Japan.
- Unadjusted mortality was higher in the post-pandemic period, suggesting confounding factors.
- The study highlights the importance of risk adjustment in evaluating pandemic-related healthcare impacts.
Background:
Infective endocarditis (IE) is a life-threatening condition with high mortality. The Coronavirus disease 2019 (COVID-19) pandemic disrupted healthcare systems, potentially affecting IE management and outcomes. However, its impact in Japan remains unclear. This study aimed to evaluate the impact of the COVID-19 pandemic on in-hospital mortality and the rate of valve surgery among patients with IE in Japan.
Methods And Results:
We conducted a retrospective analysis using the Japanese registry of all Cardiac and Vascular Diseases Diagnostic Procedure Combination (JROAD-DPC) nationwide database, including 19,077 adult patients hospitalized with IE between April 2016 and March 2022. The study period was divided into pre-COVID-19 (n=12,419) and post-COVID-19 (n=6,658) periods. Patient baseline characteristics were well-balanced after 1 : 1 propensity score matching (6,652 pairs). Before matching, crude total in-hospital mortality was higher in the post-COVID-19 period (15.7% vs. 13.9%; P<0.001). However, after matching, there were no significant differences in total in-hospital mortality (15.7% vs. 15.3%, P=0.60). The rate of valve surgery did not differ significantly between the groups after matching (26.4% vs. 25.5%; P=0.22). The incidence of stroke was higher in the post-COVID-19 period (8.3% vs. 7.3%; P=0.049).
Conclusions:
This nationwide study showed that risk-adjusted in-hospital mortality in patients with IE was not different during the COVID-19 pandemic, although unadjusted mortality was higher in the post-COVID-19 period in Japan.
Related Concept Videos
Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis III: Medical Management
Endocarditis I: Introduction
Endocarditis IV: Nursing Management
Myocarditis III: Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

